JP2022517189A5 - - Google Patents
Info
- Publication number
- JP2022517189A5 JP2022517189A5 JP2021539020A JP2021539020A JP2022517189A5 JP 2022517189 A5 JP2022517189 A5 JP 2022517189A5 JP 2021539020 A JP2021539020 A JP 2021539020A JP 2021539020 A JP2021539020 A JP 2021539020A JP 2022517189 A5 JP2022517189 A5 JP 2022517189A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- oxo
- isopropyl
- pyrimidine
- dihydropyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/070275 | 2019-01-03 | ||
| CN2019070275 | 2019-01-03 | ||
| CNPCT/CN2019/081673 | 2019-04-08 | ||
| CN2019081673 | 2019-04-08 | ||
| PCT/US2020/012058 WO2020142612A1 (en) | 2019-01-03 | 2020-01-02 | Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517189A JP2022517189A (ja) | 2022-03-07 |
| JP2022517189A5 true JP2022517189A5 (enExample) | 2023-01-04 |
| JP7539892B2 JP7539892B2 (ja) | 2024-08-26 |
Family
ID=69400641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539020A Active JP7539892B2 (ja) | 2019-01-03 | 2020-01-02 | 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12344603B2 (enExample) |
| EP (1) | EP3941919B1 (enExample) |
| JP (1) | JP7539892B2 (enExample) |
| CN (1) | CN113508115A (enExample) |
| TW (1) | TWI748317B (enExample) |
| WO (1) | WO2020142612A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI831829B (zh) | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | 苯氧基-吡啶基-嘧啶化合物及使用方法 |
| JP7539892B2 (ja) | 2019-01-03 | 2024-08-26 | ジェネンテック， インコーポレイテッド | 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物 |
| JP7611154B2 (ja) * | 2019-02-18 | 2025-01-09 | ジェネンテック， インコーポレイテッド | ピリド－ピリミジニル化合物及び使用の方法 |
| FI4073065T3 (fi) | 2019-12-10 | 2025-04-16 | Hoffmann La Roche | Uusia metyylikinatsolinonijohdannaisia |
| JP2023549540A (ja) | 2020-11-18 | 2023-11-27 | デシフェラ・ファーマシューティカルズ，エルエルシー | Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法 |
| EP4263541A1 (en) * | 2020-12-18 | 2023-10-25 | F. Hoffmann-La Roche AG | New aryl-pyrido-pyrimidin-one derivatives |
| WO2022129259A1 (en) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | New quinazolinone derivatives |
| JP2024523839A (ja) | 2021-06-08 | 2024-07-02 | シーフォー セラピューティクス， インコーポレイテッド | 突然変異体ｂｒａｆを分解する療法薬 |
| CN115850282A (zh) * | 2021-09-24 | 2023-03-28 | 华东理工大学 | 靶向降解egfr蛋白的化合物及其制备方法和应用 |
| PE20250609A1 (es) | 2021-12-03 | 2025-02-26 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos |
| WO2024131893A1 (en) * | 2022-12-22 | 2024-06-27 | Shanghai Yi Zhong Xing Biotechnology Co., Ltd. | IRE1α SMALL MOLECULE INHIBITORS |
| US12573866B2 (en) | 2023-11-17 | 2026-03-10 | Exro Technologies Inc. | Battery system for operating point control of power systems |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| KR20020027649A (ko) * | 1999-09-15 | 2002-04-13 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 카이나제 억제제로서의 프테리딘온 |
| BR0113628A (pt) * | 2000-08-31 | 2003-07-01 | Hoffmann La Roche | 7-oxo-piridopirimidinas como inibidores de uma proliferação celular |
| WO2004063195A1 (en) * | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Pyridopyrimidine kinase inhibitors |
| JP4758349B2 (ja) * | 2003-10-08 | 2011-08-24 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| AU2005245386B2 (en) | 2004-05-07 | 2008-11-27 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| CA2570494A1 (en) * | 2004-06-23 | 2006-01-05 | Irm Llc | Pteridine derivatives as protein kinase inhibitors |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US20090131430A1 (en) * | 2004-11-23 | 2009-05-21 | Palle Venkata P | Pyrido'2,3-dipyrimidines as anti-inflammatory agents |
| EP1846403A1 (en) * | 2005-02-02 | 2007-10-24 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as anti-inflammatory agents |
| US7868177B2 (en) | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| MX2008014618A (es) * | 2006-05-15 | 2008-11-28 | Irm Llc | Composiciones y metodos para inhibidores de cinasas del receptor fgf. |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| WO2008055842A1 (en) | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same |
| WO2008079933A2 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| EP2340248B1 (en) | 2008-09-15 | 2017-05-31 | The Regents of The University of California | Methods and compositions for modulating ire1, src, and abl activity |
| US9181238B2 (en) * | 2010-02-05 | 2015-11-10 | Novartis Ag | N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors |
| CA2854462A1 (en) * | 2011-11-04 | 2013-05-10 | Afraxis Holdings, Inc. | Pak inhibitors for the treatment of fragile x syndrome |
| WO2013090840A1 (en) | 2011-12-15 | 2013-06-20 | Gilead Sciences, Inc. | 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors |
| MX2015003874A (es) | 2012-09-26 | 2015-12-16 | Univ California | Modulacion de ire1. |
| US20140323478A1 (en) * | 2013-04-30 | 2014-10-30 | Afraxis Holdings, Inc. | Serine/threonine kinase inhibitors |
| US20140323477A1 (en) * | 2013-04-30 | 2014-10-30 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| CA2911706A1 (en) * | 2013-05-09 | 2014-11-13 | Principia Biopharma Inc. | Quinolone derivatives as fibroblast growth factor inhibitors |
| WO2018102751A1 (en) * | 2016-12-02 | 2018-06-07 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| TW201838981A (zh) | 2017-03-17 | 2018-11-01 | 美商建南德克公司 | 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法 |
| JP7126084B2 (ja) * | 2017-06-01 | 2022-08-26 | コーネル ユニバーシティー | Ｉｒｅ１小分子阻害薬 |
| WO2018222917A1 (en) * | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| US10392367B2 (en) | 2017-06-01 | 2019-08-27 | Quentis Therapeutics, Inc. | IRE1 small molecule inhibitors |
| TWI831829B (zh) | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | 苯氧基-吡啶基-嘧啶化合物及使用方法 |
| JP7546299B2 (ja) | 2018-12-03 | 2024-09-06 | コーネル・ユニバーシティー | Ｉｒｅ１小分子阻害物質 |
| JP7539892B2 (ja) | 2019-01-03 | 2024-08-26 | ジェネンテック， インコーポレイテッド | 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物 |
| AR118826A1 (es) | 2019-05-03 | 2021-11-03 | Kinnate Biopharma Inc | Inhibidores de cinasas raf |
| KR102396930B1 (ko) | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
-
2020
- 2020-01-02 JP JP2021539020A patent/JP7539892B2/ja active Active
- 2020-01-02 EP EP20702937.2A patent/EP3941919B1/en active Active
- 2020-01-02 WO PCT/US2020/012058 patent/WO2020142612A1/en not_active Ceased
- 2020-01-02 TW TW109100113A patent/TWI748317B/zh active
- 2020-01-02 CN CN202080017509.0A patent/CN113508115A/zh active Pending
-
2021
- 2021-07-02 US US17/366,923 patent/US12344603B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6754864B2 (ja) | Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物 | |
| JP2026009899A (ja) | ＮａＶ１．８を阻害するピリジンカルボキサミド化合物 | |
| JP6736559B2 (ja) | トリアゾロピリミジン化合物およびその使用 | |
| JP2025508702A (ja) | キナゾリン化合物、及び変異ｋｒａｓタンパク質の阻害剤としてのその使用 | |
| JP2021524484A5 (enExample) | ||
| KR20010050223A (ko) | Ｃｒｆ 길항제 및 관련 조성물의 용도 | |
| JP7539892B2 (ja) | 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物 | |
| ES2798424T3 (es) | Compuestos de triazolopiridina y usos de estos | |
| JP7611154B2 (ja) | ピリド－ピリミジニル化合物及び使用の方法 | |
| KR20260047565A (ko) | 통증에 대한 신규 치료 | |
| JP2005538099A5 (enExample) | ||
| JP2011510995A5 (enExample) | ||
| JP2013056930A5 (enExample) | ||
| JP7320600B2 (ja) | フェノキシ－ピリジル－ピリミジン化合物及び使用方法 | |
| RU2009125916A (ru) | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения | |
| JP7768880B2 (ja) | Ｅｚｈ２を阻害するためのキノリン化合物および組成物 | |
| JP2022539830A5 (enExample) | ||
| JP2022550353A (ja) | アザキノリン化合物およびその使用 | |
| KR20170129757A (ko) | Fgfr4 억제제로서의 포르밀화 n-헤테로시클릭 유도체 | |
| US20240245634A1 (en) | Pcna inhibitors and egfr inhibitors for cancer treatment | |
| WO2020176501A1 (en) | Compounds useful for inhibiting raf dimers | |
| TWI691500B (zh) | 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物 | |
| RU2393157C1 (ru) | 2-АЛКИЛАМИНО-3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| HK40097521A (zh) | 三环类化合物及其用途 | |
| HK40080941A (en) | Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases |